Anatara Lifesciences has announced that it has received a second payment under the exclusive Evaluation and License Option Agreement with the leading global animal health company Zoetis Inc. for Detach, Anatara's non-antibiotic anti-infective product. Under terms of the agreement which was initially announced on the 18th January 2016, Zoetis has exclusive rights to evaluate the potential applications of DetachTM for veterinary use in food production animals. Anatara has granted Zoetis an option to license DetachTM for development and commercialization in markets worldwide while retaining rights to the Australian and New Zealand markets.

The companies agreed on a research program for investigation of the utility in multiple livestock species during the option period.